Scienture is a pharmaceutical company that markets and develops prescription medicines for heart and nervous system diseases. It last closed at $2.76 on Nov 17, down 7.69% on the day.
Only 1 firm rated SCNX in the past 90 days, not enough for a consensus
Average 12-month target
$6.00
▲ 117.4% upside
Based on 1 analyst who set a price target on SCNX in the past 90 days. The average target is $6.00, with a high of $6.00 and a low of $6.00, compared with the last close of $2.76.
Low $6.00Avg $6.00High $6.00
Blue marker: last close $2.76
Highest target$6.00
Average target$6.00
Lowest target$6.00
Latest rating changes
Maxim GroupMaintained
Oct 23Buy$6
Date
Firm
Action
Rating
Price target
Oct 23
Maxim Group
Maintained
Buy
$6
Loading…
Technical Analysis
SCNX · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold
The stock is 12% below its 20 day and 71% below its 50 day average. It is 213% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 30), near oversold. The nearest support is the Pivot S1 at $2.66, and the nearest resistance the Pivot at $2.83.
Short trendBearish
Long trendBearish
MomentumFading
StretchNear oversold
VolatilityNormal, 11.4%/day
Key levels
$18.7552 week high+579.3%
$8.63200 day average+212.7%
$7.27100 day average+163.4%
$4.7350 day average+71.4%
$3.46Swing high (Nov 4)+25.4%
$3.1020 day average+12.3%
$2.93Pivot R1+6.2%
$2.83Pivot+2.5%
$2.76Last close
$2.66Pivot S1−3.6%
$2.6452 week low−4.3%
$2.64Swing low (Oct 23)−4.3%
Indicators
RSI (14)
30.35
Weak, oversold below 30
Neutral
MACD
-0.46
Above its signal line
Bullish
Stochastic
11.3
Near the bottom of its range
Oversold
ADX (14)
38.7
Trending down
Williams %R
-96.8
Oversold below −80, overbought above −20
Oversold
CCI (20)
-110.2
Oversold below −100, overbought above 100
Oversold
Rate of change
−20.0%
Change over 10 sessions
Bearish
ATR (14)
$0.32
Typical daily range, 11.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Falling, oversold
Short trendBearish
Long trendNot enough history
MomentumWeak
StretchOversold
VolatilityNormal, 57.5%/day
Key levels
$18.7552 week high+579.3%
$8.63200 day average+212.7%
$7.27100 day average+163.4%
$4.7350 day average+71.4%
$3.46Swing high (Nov 4)+25.4%
$3.1020 day average+12.3%
$2.93Pivot R1+6.2%
$2.83Pivot+2.5%
$2.76Last close
$2.66Pivot S1−3.6%
$2.6452 week low−4.3%
$2.64Swing low (Oct 23)−4.3%
Indicators
RSI (14)
27.73
Oversold below 30
Oversold
MACD
-2.36
Below its signal line
Bearish
Stochastic
3.1
Near the bottom of its range
Oversold
ADX (14)
21.3
Weak trend
Williams %R
-98.7
Oversold below −80, overbought above −20
Oversold
CCI (20)
-94.7
Oversold below −100, overbought above 100
Neutral
Rate of change
−68.3%
Change over 10 sessions
Bearish
ATR (14)
$1.59
Typical daily range, 57.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200–
What happened before, for SCNX
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how SCNX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Whale Options Flow
90D
No whale options trades in SCNX in the last 90 days.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SCNX is in one of them and how their past SCNX trades turned out.
Scienture is a specialty pharmaceutical company based in Commack, New York. It markets and develops prescription medicines for cardiovascular and central nervous system conditions, serving patients in the United States. Its marketed products include an oral liquid form of losartan for high blood pressure and a nasal spray naloxone product for opioid overdose. The company also has a pipeline of candidate treatments for conditions such as migraine, blood clots, and pain.